Building upon these preclinical successes, the first human clinical trial targeting retinal degeneration in BBS is currently in development; AXV-101 is an investigational gene therapy designed specifically for patients with the missense BBS1 M390R mutation, the most common genetic cause of BBS [60]. Here, BBS1 is linked to Bardet-Biedl syndrome.